Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma

[1]  J. H. Richardson,et al.  The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models , 2016, Oncogene.

[2]  Prasenjit Dey,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[3]  Nicholas J. Wang,et al.  Functionally-defined Therapeutic Targets in Diffuse Intrinsic Pontine Glioma , 2015, Nature Medicine.

[4]  Michael A. Choti,et al.  Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets , 2015, Nature Communications.

[5]  E. Collisson,et al.  Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation , 2015, Genes & development.

[6]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[7]  W. Gradishar,et al.  ERK-regulated αB-Crystallin Induction by Matrix Detachment Inhibits Anoikis and Promotes Lung Metastasis in vivo , 2015, Oncogene.

[8]  Eric Legius,et al.  PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies , 2014, Nature.

[9]  Francisco J. Sánchez-Rivera,et al.  Rapid modeling of cooperating genetic events in cancer through somatic genome editing , 2014, Nature.

[10]  G. Wahl,et al.  Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.

[11]  Joon-Oh Park,et al.  A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. , 2014, European journal of cancer.

[12]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[13]  A. Butte,et al.  SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer , 2014, Nature.

[14]  A. Maitra,et al.  Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. , 2014, Cancer cell.

[15]  D. Bentrem,et al.  Cancer Biology and Signal Transduction Bet Bromodomain Inhibitors Block Growth of Pancreatic Cancer Cells in Three-dimensional Collagen , 2022 .

[16]  C. Hajdu,et al.  Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. , 2014, The Journal of clinical investigation.

[17]  M. Pasca di Magliano,et al.  Kras as a key oncogene and therapeutic target in pancreatic cancer , 2014, Front. Physiol..

[18]  N. Bardeesy,et al.  Pancreatic adenocarcinoma. , 2014, The New England journal of medicine.

[19]  David A. Scott,et al.  Genome engineering using the CRISPR-Cas9 system , 2013, Nature Protocols.

[20]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[21]  Alexander A. Morgan,et al.  A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation , 2013, The Journal of experimental medicine.

[22]  Travis J Cohoon,et al.  Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.

[23]  Eli J. Fine,et al.  DNA targeting specificity of RNA-guided Cas9 nucleases , 2013, Nature Biotechnology.

[24]  Ashley M. Zehnder,et al.  IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase–driven tumors , 2013, Nature Medicine.

[25]  David A. Orlando,et al.  Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers , 2013, Cell.

[26]  R. Zhao,et al.  CDK inhibitor p57Kip2 is downregulated by Akt during HER2-mediated tumorigenicity , 2013, Cell cycle.

[27]  M. Fabbri,et al.  Insights into the epigenetic mechanisms controlling pancreatic carcinogenesis. , 2013, Cancer letters.

[28]  R. Alemany,et al.  Intraductal Delivery of Adenoviruses Targets Pancreatic Tumors in Transgenic Ela-myc Mice and Orthotopic Xenografts , 2013, Oncotarget.

[29]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[30]  Jens T Siveke,et al.  EGF receptor is required for KRAS-induced pancreatic tumorigenesis. , 2012, Cancer cell.

[31]  Julio E. Agno,et al.  Small-Molecule Inhibition of BRDT for Male Contraception , 2012, Cell.

[32]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[33]  Bond-Smith Giles,et al.  Only women with symptoms need to have their breast implants removed, says government , 2012 .

[34]  Natalie Cook,et al.  Predictive in vivo animal models and translation to clinical trials. , 2012, Drug discovery today.

[35]  S. Lowe,et al.  RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia , 2011, Nature.

[36]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[37]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[38]  D. Levy,et al.  STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.

[39]  M. Barbacid,et al.  Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. , 2011, Cancer cell.

[40]  D. Hanahan,et al.  Endogenous Myc maintains the tumor microenvironment. , 2011, Genes & development.

[41]  S. Akira,et al.  Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. , 2011, Cancer cell.

[42]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[43]  Francisco J. Sánchez-Rivera,et al.  Stage-specific sensitivity to p53 restoration during lung cancer progression , 2010, Nature.

[44]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[45]  R. Rad,et al.  Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma , 2010, Proceedings of the National Academy of Sciences.

[46]  Mallika Singh,et al.  Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models , 2010, Nature Biotechnology.

[47]  M. Hebrok,et al.  Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. , 2010, The Journal of clinical investigation.

[48]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[49]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[50]  Allan R. Jones,et al.  A robust and high-throughput Cre reporting and characterization system for the whole mouse brain , 2009, Nature Neuroscience.

[51]  J. Campisi,et al.  Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo , 2009, Nature Protocols.

[52]  Gerald C. Chu,et al.  Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. , 2009, Cancer cell.

[53]  C. Peterson,et al.  Chromatin immunoprecipitation (ChIP). , 2009, Cold Spring Harbor protocols.

[54]  David Allard,et al.  Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer , 2009, Science.

[55]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[56]  Douglas B. Evans,et al.  Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice , 2009, Nature Protocols.

[57]  R. Hruban,et al.  Pancreatic cancer. , 2021, Annual review of pathology.

[58]  B. Joseph,et al.  The cell cycle inhibitor p57Kip2 promotes cell death via the mitochondrial apoptotic pathway , 2007, Cell Death and Differentiation.

[59]  J. Neoptolemos,et al.  A new approach to managing intraductal papillary mucinous pancreatic neoplasms , 2007, Gut.

[60]  Eithne Costello,et al.  Biology and management of pancreatic cancer , 2007, Postgraduate Medical Journal.

[61]  M. Barbacid,et al.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.

[62]  Gerald C. Chu,et al.  Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. , 2006, Genes & development.

[63]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[64]  Ralph Weissleder,et al.  Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[65]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[66]  I. Verma,et al.  Production and purification of lentiviral vectors , 2006, Nature Protocols.

[67]  E. Furth,et al.  Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. , 2006, Cancer research.

[68]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[69]  S. Leach,et al.  Pancreatic epithelial plasticity mediated by acinar cell transdifferentiation and generation of nestin-positive intermediates , 2005, Development.

[70]  M. Goggins,et al.  Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling , 2005, Clinical Cancer Research.

[71]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[72]  J. Durocher,et al.  Mutation detection using Surveyor nuclease. , 2004, BioTechniques.

[73]  J. Durocher,et al.  Mutation detection using Surveyor TM nuclease , 2004 .

[74]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[75]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[76]  T. Möröy,et al.  Miz1 Is Required for Early Embryonic Development during Gastrulation , 2003, Molecular and Cellular Biology.

[77]  R. DePinho,et al.  Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.

[78]  C. Wright,et al.  The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors , 2002, Nature Genetics.

[79]  John D. Storey.  A direct approach to false discovery rates , 2002 .

[80]  H. Zentgraf,et al.  c-MYC Activation in Primary and Metastatic Ductal Adenocarcinoma of the Pancreas: Incidence, Mechanisms, and Clinical Significance , 2002, Modern Pathology.

[81]  A. Berns,et al.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer , 2001, Nature Genetics.

[82]  M. Kawaichi,et al.  p48 subunit of mouse PTF1 binds to RBP‐Jκ/CBF‐1, the intracellular mediator of Notch signalling, and is expressed in the neural tube of early stage embryos , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[83]  F. Alt,et al.  Analysis of C-MYC function in normal cells via conditional gene-targeted mutation. , 2001, Immunity.

[84]  M. Barbacid,et al.  Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. , 1997, Genes & development.